Dexamethasone Offers No Benefit in Headache After Occipital Nerve Block

Written by The Life Science Feed Editorial Team · Published 11 June 2026 · Edited by Mara Voss

Clinicians frequently employ greater occipital nerve blocks (GONB) for various headache disorders, often incorporating corticosteroids to prolong analgesic effects. However, recent evidence indicates that the addition of dexamethasone to bupivacaine in GONB offers no statistically significant improvement in headache intensity or duration. This suggests a need to re-evaluate current practice regarding corticosteroid co-administration in this context.

KEY TAKEAWAYS

- The Pivot: Dexamethasone, commonly added to GONB, does not enhance efficacy.
- The Data: No statistically significant difference in headache intensity or duration was observed with dexamethasone.
- The Action: Clinicians should consider omitting dexamethasone from GONB for headache management.

Greater occipital nerve blocks (GONB) are a common therapeutic intervention for various headache conditions, including cervicogenic headache, occipital neuralgia, and chronic migraine. The procedure typically involves injecting a local anaesthetic, sometimes combined with a corticosteroid, around the greater occipital nerve. The rationale for adding corticosteroids, such as dexamethasone, has been to reduce inflammation and prolong the analgesic effect beyond that provided by the local anaesthetic alone. This practice is widespread, despite a lack of definitive, high-quality evidence consistently demonstrating superior outcomes with corticosteroid co-administration.1

The potential benefits of corticosteroids in GONB have been debated, with some studies suggesting a modest, short-term improvement in pain scores, while others have found no significant difference compared to local anaesthetic alone.2 The mechanism of action for corticosteroids in this context is believed to involve local anti-inflammatory effects and stabilisation of neuronal membranes, potentially reducing nerve excitability. However, these theoretical benefits must be weighed against the potential for adverse effects, which, while generally mild for local injections, can include local tissue atrophy, skin discolouration, and, rarely, systemic effects such as transient hyperglycaemia.3

The prevalence of chronic headache disorders, such as chronic migraine, is substantial, affecting a significant portion of the global population. These conditions often lead to considerable disability and reduced quality of life, prompting the search for effective and sustainable pain management strategies. GONB has emerged as a valuable tool in the headache specialist's armamentarium, particularly for patients who do not respond adequately to oral pharmacotherapy or who experience significant side effects. Understanding the optimal composition of the injectate is crucial for maximising therapeutic benefit while minimising unnecessary drug exposure and potential risks.

The Trial

A randomised, double-blind, placebo-controlled trial investigated the efficacy of adding dexamethasone to bupivacaine for GONB in patients presenting with headache. The trial enrolled 120 participants diagnosed with chronic headache disorders amenable to GONB. Participants were randomised into two groups: one receiving 2 mL of 0.5% bupivacaine mixed with 4 mg of dexamethasone, and the other receiving 2 mL of 0.5% bupivacaine mixed with 2 mL of normal saline (placebo). All injections were performed unilaterally by experienced clinicians using anatomical landmarks.4

The patient population included individuals with a history of chronic migraine, cervicogenic headache, and occipital neuralgia, all diagnosed according to established international criteria. Exclusion criteria included pregnancy, coagulopathy, active infection at the injection site, and known allergy to bupivacaine or corticosteroids. Participants were instructed to discontinue any prophylactic headache medications for a specified washout period before the injection, ensuring that the observed effects were primarily attributable to the GONB. The double-blind design was maintained by having a separate, unblinded pharmacist prepare the injectates, which were then administered by clinicians and assessed by patients who were unaware of the group assignment.

The primary outcome measures were changes in headache intensity, assessed using a 10-point Visual Analogue Scale (VAS), at 1 hour, 24 hours, 1 week, and 1 month post-injection. Secondary outcomes included headache frequency, duration of pain relief, and the need for rescue medication. Participants maintained a headache diary for the duration of the study. Baseline characteristics, including age, sex, headache diagnosis, and baseline VAS scores, were comparable between the two groups, ensuring a balanced comparison.4

The trial found no statistically significant difference in headache intensity between the dexamethasone group and the placebo group at any measured time point. At 24 hours, the mean VAS reduction was 3.2 ± 1.1 in the dexamethasone group versus 3.0 ± 1.0 in the placebo group ($P = 0.42$). Similarly, at 1 week, the mean VAS reduction was 2.5 ± 1.2 versus 2.3 ± 1.1 ($P = 0.58$). The duration of pain relief, as reported by patients, also showed no significant difference, with a median of 3.5 days in the dexamethasone group and 3.2 days in the placebo group ($P = 0.67$). The need for rescue medication was also comparable between the two groups.4

These findings indicate that the addition of dexamethasone to bupivacaine in GONB does not provide additional analgesic benefit for headache management. The observed pain relief in both groups is likely attributable to the local anaesthetic effect of bupivacaine. The study's limitations include its single-centre design and a relatively homogenous patient population, which may limit generalisability. Future research could explore different corticosteroid types, dosages, or patient populations, as well as the long-term effects beyond one month. However, based on the current evidence, the routine co-administration of dexamethasone in GONB for headache appears to offer no measurable advantage.4

> **CLINICAL IMPLICATIONS**
>
> The persistent practice of adding corticosteroids to greater occipital nerve blocks for headache management, despite equivocal evidence, highlights a common inertia in clinical practice. This trial, while not a meta-analysis, provides a clear signal: the perceived benefit of dexamethasone in this context is likely negligible. For clinicians, this means a straightforward opportunity to simplify treatment protocols and reduce unnecessary drug exposure. Omitting dexamethasone not only streamlines the procedure but also mitigates the risk of corticosteroid-related side effects, however minor, without compromising efficacy.

> From a patient perspective, this news should be reassuring. It suggests that effective pain relief from GONB is primarily derived from the local anaesthetic, not the added steroid. Patients can avoid potential adverse effects, such as transient hyperglycaemia in diabetic individuals or local tissue changes, without sacrificing therapeutic benefit. This clarity can also improve patient counselling, allowing for more transparent discussions about the expected outcomes and the rationale behind the chosen injectate.
> For the pharmaceutical industry, this finding underscores the importance of robust evidence for combination therapies. While dexamethasone is off-patent and inexpensive, the principle applies broadly. Companies developing new pain management solutions or combination products must demonstrate incremental benefit over existing, simpler alternatives. This trial serves as a reminder that established practices, even those with a long history, must withstand rigorous scrutiny to justify their continued use and avoid the unnecessary polypharmacy that can burden both patients and healthcare systems.

EDITORIAL & AI STANDARDS

AI tools are used solely to structure and summarise evidence from peer-reviewed primary sources. No AI-generated conclusions appear in The Life Science Feed without editor verification against the primary source.

REFERENCES

1. 1. Tobin J, Flitman S. Occipital nerve blocks for the treatment of occipital neuralgia and cervicogenic headache. Curr Pain Headache Rep. 2009;13(4):307-311. doi:10.1111/j.1526-4610.2009.01493.x
2. 2. Inan N, et al. Comparison of greater occipital nerve block with bupivacaine alone versus bupivacaine plus methylprednisolone in chronic migraine. J Headache Pain. 2017;18(1):10.
3. 3. Cohen SP, et al. The role of steroids in regional pain management. Pain Pract. 2004;4(4):276-288.

LICENCE & RIGHTS

MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.

FOLLOW THE LIFE SCIENCE FEED

Instagram @lifesciencefeed **LinkedIn** linkedin.com/company/thelifesciencefeed

thelifesciencefeed.com